Skin biomarkers for diagnosing and characterizing AD and ADRD

用于诊断和表征 AD 和 ADRD 的皮肤生物标志物

基本信息

  • 批准号:
    10673714
  • 负责人:
  • 金额:
    $ 75.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-30 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT Alzheimer's disease (AD) and AD-related dementias (ADRD) such as Lewy body dementia (LBD) are all associated with deposition of misfolded protein aggregates in the brain including tau in AD and non-AD tauopathies, and α-synuclein (αSyn) in LBD. Currently, a definite diagnosis of these disorders relies on the histological and biochemical examination of the brain for the misfolded proteins. Development of reliable and sensitive assays for these misfolded proteins in easily accessible peripheral specimens is critical for early or differential diagnosis, determination of disease severity, and evaluation of therapeutic efficacy in clinical trials. Interestingly, brain tau and αSyn aggregates exhibit prion-like aggregation seeding activity, which can be specifically detected by two highly sensitive amplification assays including real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA). They have been proved to be highly sensitive for detection of misfolded proteins in the brain and/or cerebrospinal fluid in prion disease (PrD), AD, or PD (Atarashi et al., 2011; Peden et al., 2012; Foutz et al., 2017; Orrú et al., 2015; Saijo et al., 2017; Kraus et al., 2018). Using RT-QuIC/PMCA, we were able to detect prion and αSyn aggregates in the skin of individuals with PrD or PD (Orrú et al., 2017; Wang et al., 2019; 2020). Remarkably, our preliminary results have shown that prions-like tau- seeding activity is detectable by RT-QuIC and PMCA in skin of AD patients but not in normal controls. Thus, we hypothesize that skin tau-seeding activity detected by RT-QuIC and PMCA is a novel biomarker for diagnosing, characterizing, and predicting outcomes of AD and non-AD tauopathies and for differentiating AD from LBD. To test this hypothesis, the following four Aims will be pursued: (1) Establish the tau-seeding activity in autopsied skin samples as a biomarker for POSTMORTEM diagnosis and characterization of AD using RT-QuIC/PMCA assays; (2) Assess skin tau-seeding activity as a biomarker for PREMORTEM diagnosis, characterization, and predicting clinical outcomes of AD; (3) Determine skin tau-seeding activity as a biomarker for differentiating AD from non-AD tauopathies, and from LBD, a common ADRD; and (4) Determine whether skin tau-seeding activity is detectable at an asymptomatic stage by RT-QuIC/PMCA in animal models of AD tauopathies. We believe that the successful implementation of this project will develop RT-QuIC/PMCA assays of skin tau-seeding activity as a biomarker for diagnostic testing and evaluating clinical trials across AD, non-AD tauopathies, and LBD.
抽象的 阿尔茨海默氏病(AD)和与AD相关的痴呆症(ADRD),例如Lewy身体痴呆症(LBD)都是 与大脑中错误折叠蛋白聚集体的沉积有关,包括AD和非AD LBD中的tauopathies和α-突触核蛋白(αSyn)。目前,这些疾病的定义诊断依赖于 对错误折叠蛋白的大脑的组织学和生化检查。开发可靠和 这些错误折叠蛋白在易于访问的外围样品中的敏感测定对于早期或 在临床试验中,鉴别诊断,疾病严重程度的确定以及对治疗效率的评估。 有趣的是,脑tau和αSyn聚集体表现出类似prion的聚集活性,这可以是 由两个高度敏感的扩增测定法特别检测 (RT-Quic)和蛋白质错误折叠环状扩增(PMCA)。事实证明它们对 检测大脑中错误折叠的蛋白质和/或脑脊液中的脑脊液(PRD),AD或PD(Atarashi)(Atarashi) 等,2011; Peden等人,2012年; Foutz等人,2017年; Orrú等,2015; Saijo等人,2017年; Kraus等,2018)。使用 rt-Quic/pmca,我们能够检测到具有PRD或PD的个体皮肤中的Prion和αSyn骨料 (Orrú等,2017; Wang等,2019; 2020)。值得注意的是,我们的初步结果表明,像王子一样 在AD患者的皮肤中,RT-Quic和PMCA可以检测到播种活性,但在正常对照组中不能检测到。那,我们 假设RT-Quic和PMCA检测到的皮肤tau种子活性是一种新颖的生物标志物 诊断,表征和预测AD和非AD tauopathies的结果以及 将广告与LBD区分开。为了检验这一假设,将追求以下四个目标:(1)确定 尸体式皮肤样品中的tau种子活性是验尸诊断和表征的生物标志物 使用RT-QUIC/PMCA分析的AD; (2)评估皮肤tau种子活性作为Premortem的生物标志物 诊断,表征和预测AD的临床结果; (3)确定皮肤tau种子活性 生物标志物用于将广告与非AD tauopathies区分开,而LBD是常见的ADRD; (4)确定 在动物模型中,RT-Quic/PMCA是否可以在不对称阶段检测到皮肤tau播种活性 广告tauopathies。我们认为,该项目的成功实施将开发RT-Quic/PMCA 皮肤tau种子活性作为诊断测试和评估AD临床试验的生物标志物的测定 非AD tauopathies和LBD。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Selective Detection of Misfolded Tau From Postmortem Alzheimer's Disease Brains.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHU G. CHEN其他文献

SHU G. CHEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHU G. CHEN', 18)}}的其他基金

Peripheral Biomarkers for Early Diagnosis of Mixed Pathologies in AD/ADRD
用于 AD/ADRD 混合病理早期诊断的外周生物标志物
  • 批准号:
    10669877
  • 财政年份:
    2023
  • 资助金额:
    $ 75.78万
  • 项目类别:
Skin biomarkers for diagnosing and characterizing AD and ADRD
用于诊断和表征 AD 和 ADRD 的皮肤生物标志物
  • 批准号:
    10307911
  • 财政年份:
    2021
  • 资助金额:
    $ 75.78万
  • 项目类别:
Skin biomarkers for diagnosing and characterizing AD and ADRD
用于诊断和表征 AD 和 ADRD 的皮肤生物标志物
  • 批准号:
    10491802
  • 财政年份:
    2021
  • 资助金额:
    $ 75.78万
  • 项目类别:
Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia
用于路易体痴呆死前诊断的外周组织生物标志物
  • 批准号:
    10705299
  • 财政年份:
    2021
  • 资助金额:
    $ 75.78万
  • 项目类别:
Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia
用于路易体痴呆死前诊断的外周组织生物标志物
  • 批准号:
    10653599
  • 财政年份:
    2021
  • 资助金额:
    $ 75.78万
  • 项目类别:
Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia
用于路易体痴呆死前诊断的外周组织生物标志物
  • 批准号:
    10248548
  • 财政年份:
    2020
  • 资助金额:
    $ 75.78万
  • 项目类别:
Peripheral Tissue Biomarker for Premorten Diagnosis of Lewy Body Dementia
用于路易体痴呆临终诊断的外周组织生物标志物
  • 批准号:
    10401974
  • 财政年份:
    2020
  • 资助金额:
    $ 75.78万
  • 项目类别:
Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia
用于路易体痴呆死前诊断的外周组织生物标志物
  • 批准号:
    10064737
  • 财政年份:
    2020
  • 资助金额:
    $ 75.78万
  • 项目类别:
Assessing skin biomarkers for preclinical diagnosis of PD and non-PD Parkinsonism
评估皮肤生物标志物用于帕金森病和非帕金森病的临床前诊断
  • 批准号:
    10256807
  • 财政年份:
    2019
  • 资助金额:
    $ 75.78万
  • 项目类别:
Assessing skin biomarkers for preclinical diagnosis of PD and non-PD Parkinsonism
评估皮肤生物标志物用于帕金森病和非帕金森病的临床前诊断
  • 批准号:
    10622565
  • 财政年份:
    2019
  • 资助金额:
    $ 75.78万
  • 项目类别:

相似海外基金

The Influence of Lifetime Occupational Experience on Cognitive Trajectories Among Mexican Older Adults
终生职业经历对墨西哥老年人认知轨迹的影响
  • 批准号:
    10748606
  • 财政年份:
    2024
  • 资助金额:
    $ 75.78万
  • 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
  • 批准号:
    10749539
  • 财政年份:
    2024
  • 资助金额:
    $ 75.78万
  • 项目类别:
Individual Predoctoral Fellowship
个人博士前奖学金
  • 批准号:
    10752036
  • 财政年份:
    2024
  • 资助金额:
    $ 75.78万
  • 项目类别:
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimer's Disease
从肉体到细丝的流畅性:多尺度神经影像数据的整理、表示和分析,以表征和诊断阿尔茨海默病
  • 批准号:
    10462257
  • 财政年份:
    2023
  • 资助金额:
    $ 75.78万
  • 项目类别:
Core D: Integrated Computational Analysis Core
核心D:综合计算分析核心
  • 批准号:
    10555896
  • 财政年份:
    2023
  • 资助金额:
    $ 75.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了